Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

GS-0201

Small molecule · Inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) · developed by GILEAD SCIENCES

Phase 1 Most advanced trial
GILD Developer
1 Registered trials

What is GS-0201?

GS-0201 is an orally bioavailable small molecule that selectively binds and inhibits PARP1, a nuclear enzyme involved in repairing DNA single-strand and double-strand breaks. By blocking base excision repair, it promotes DNA strand break accumulation and genomic instability, leading to apoptosis. It is being studied in advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
poly(ADP-ribose) polymerase 1 (PARP1)
Mechanism
Inhibitor of poly(ADP-ribose) polymerase 1 (PARP1)
Pathways
base excision repair, DNA single-strand break repair, double-strand break repair
Therapy area
Oncology
Developer
GILEAD SCIENCES (GILD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06167317 Phase 1 Advanced Solid Tumors Recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumors

Other drugs acting on PARP1

More from GILEAD SCIENCES

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind GS-0201

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.